Market Newsdesk

ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development.

“We are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,” said Larry (Lei) Xiao, Ph.D., ICT’s Founder and Chief Executive Officer. “His extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance our programs into the clinic in the United States.”

ICT has achieved compelling clinical response data in China, with an aggregate 60% Overall Response Rate (ORR) and 20% Complete Remission (CR) rate in 10 third-line patients. The seven colorectal cancer patients (57% ORR / 14% CR), and the three thyroid cancer patients (67% ORR / 33% CR), were treated with the Company’s in-house developed proprietary CoupledCAR^® solid tumor CAR-T platform technology. ICT remains on track to submit U.S. Investigational New Drug (IND) applications in these two indications in 2021.  

“We are confident that our colorectal and thyroid cancer programs have been significantly de-risked. This confidence is based on the outcomes of our recent clinical proof-of-concept trials, which were conducted in patients who had exhausted all available treatment options, across four hospital sites through our Shanghai-based R&D center,” said Dr. Xiao.

Dr. Kennedy is a surgical oncologist who most recently served as Chief Medical Officer of Lumos Pharma (Lumos) and, prior to its merger with Lumos, of NewLink Genetics (NewLink). Before that, he served as NewLink’s Vice President for Clinical and Medical Affairs. In these roles, Dr. Kennedy was responsible for design, implementation, and execution of all Phase 1-3 clinical trials and for overseeing medical affairs and regulatory strategy. Dr. Kennedy has filed multiple INDs for both small molecule and biologic drug candidates.

Prior to joining NewLink, Dr. Kennedy had an academic career as Associate Professor of Surgery at Thomas Jefferson University in Philadelphia, Assistant Professor of Surgery at Louisiana State University in New Orleans, and Instructor of Surgery at the Johns Hopkins School of Medicine in Baltimore.

Dr. Kennedy received a B.A. from the University of Virginia in Charlottesville and his M.D. from the Medical College of Virginia in Richmond. He obtained his General Surgical residency and Surgical Oncology fellowship training, along with a post-doctoral fellowship in immuno-oncology, at Johns Hopkins. He also completed additional surgical training at the Royal College of Surgeons in Ireland School of Medicine Beaumont Hospital in Dublin, Ireland.

“I am extremely excited about the progress of Innovative Cellular Therapeutics’ colorectal and thyroid cancer programs towards U.S. clinical trials, and about the potential of the company’s CoupledCAR^® solid tumor CAR-T platform technology in additional future indications,” said Dr. Kennedy. “The responses achieved in the company’s proof-of-concept trials in third-line colorectal and third-line thyroid cancer patients in China, and the extent to which these responses have already been confirmed in evaluations by top U.S. and Chinese independent third-party reviewing institutions, are remarkable and unprecedented. I am focused on bringing these revolutionary new therapies to cancer patients around the globe.”

About Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company’s proprietary CoupledCAR^® solid tumor CAR-T platform technology. ICT has already achieved promising responses with CoupledCAR^® in third-line colorectal and third-line thyroid cancer patients in ongoing clinical proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through the Company’s Shanghai-based R&D center. ICT received its first U.S. Investigational New Drug (IND) application clearance for its ICTCAR014 program in late 2019. ICTCAR014 is based on ICT’s in-house developed proprietary ArmoredCAR^® liquid tumor CAR-T platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit www.ictbio.com.

Investor Relations Contacts:		Media Relations Contact:
Morten Marott, CFO		Kate L. Barrette
Innovative Cellular Therapeutics		RooneyPartners LLC
[email protected]		212-223-0561
		[email protected]
Irina Koffler LifeSci Advisors 646-970-4681 [email protected]

Oakland, March 16, 2021 (GLOBE NEWSWIRE) — Deem, a leading mobile and cloud technology provider for the corporate travel industry, today announced its partnership with travel management company FCM. Both companies place a high value on their focus on people and innovative technology, resulting in an enormous opportunity for the businesses to continue collaborating following the initial success of shared customer, Toyota.

“Our global clients, large and small, tell us that Deem offers a unique blend of innovative technology and people who have an unmatched level of attentiveness to customer needs and expectations,” said Deem President David Grace. “Those two elements provide a platform that allows us to place the traveler at the heart of everything we do. We’re confident that partnering with FCM and the exceptional focus on white glove service and advanced tech will help us further our mission to transform travel.” 

“FCM values partnerships,“ said Billy McDonough, President of FCM Travel Solutions, Americas. “The team at Deem has been fantastic to work with and their shared interest in the customer experience resonates so well with our culture. The opportunities for future partnerships are endless when you have a partnership that values the same things – our people and our customers.”

The Deem platform was one of the key pieces of success for Toyota. As customers are finding they need to pivot in these uncertain times, Deem’s agility allows it to create innovative travel technology solutions to help customers regain their footing and continue moving forward.

A prime example is Deem’s new Travel SafetyCheck feature, which was conceived, built and delivered in just 90 days. Travel SafetyCheck provides COVID-19 and other safety information for flights and hotels within the booking flow, so travelers have the exact information they need at the time they need it most.

“I want to thank Deem from the bottom of my heart for the SafetyCheck enhancement,” said Rebecca Jeffries, travel services manager at Toyota. “We spent a lot of time creating information pages and providing links to supplier sites so our travelers can find the safety protocols, but this puts it (and more!) at the point of booking and makes it so much simpler to digest. It is brilliant!”

For more information on Travel SafetyCheck, visit Deem.com/SafetyCheck.

 

About FCM Travel Solutions: 
FCM Travel Solutions is one of the largest travel management companies in the world, and the flagship global business travel division of Flight Centre Travel Group. FCM’s network spans 97+ countries, employing over 6000 staff. At the heart of FCM’s business model are our highly experienced people who operate in small teams and are empowered to deliver exceptional customer service to their clients. We never use call centers. The combination of our people’s expertise, supplier relations, unrivaled negotiating strength and innovative technology solutions, has positioned FCM as a leading business travel partner for large national, multi-national and global corporations. For the last eight consecutive years FCM has been named the World’s Leading Travel Management Company at the World Travel Awards. www.fcmtravel.com 

 

About Deem

Deem is on a mission to transform travel. With its corporate travel booking and management platform that allows travel managers to customize their programs, Deem offers employees everything they need to easily make the right travel decisions for themselves and their company. Deem’s travel technology plugs into major travel agencies and expense solution providers, enabling more corporate customers and the world’s largest travel management companies.

Deem, a wholly owned and independently run subsidiary of Enterprise Holdings, is now part of the fifth largest travel company in the world. The company is headquartered in Oakland, California, with offices in Dublin, Ireland and Bangalore, India. Learn more at Deem.com.

 

Diana Brandon
Deem
415-590-8414
[email protected]

Novel immuno-oncology
algorithm
may offer independent and incremental predictive value over current standard biomarkers in the clinic

Data suggest that measuring the tumor microenvironment (TME) as a whole may help optimize immunotherapy use in the clinical setting

Authors concluded that the immuno-oncology algorithm is capable of analyzing data from multiple platforms that have a wide global installed base, including PCR and NGS, and from gene expression data already available from pharma clinical trials without the need for any tissue

IRVINE, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced findings from a study using the DetermaIO™ immuno-oncology algorithm to assess patients likely to benefit from immunotherapy across multiple cancer types. The study, “A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies,” was recently published in a peer-reviewed article in Heliyon, and is accessible at this link.

Immunotherapies using immune checkpoint inhibitors (ICIs) are widely considered standard of care in the treatment of lung cancer, breast cancer, and other solid tumor types. However, while ICI therapies have been shown to improve clinical outcomes for certain patients, data indicate that only 20-40% of the approximately 750,000 patients in the US eligible annually for ICI respond to those therapies. In addition, ICI therapies have been shown to cause adverse immune-related events that can be life-threatening for some patients. Standard of care PD-L1 testing incorrectly identifies many patients as potential responders to immune checkpoint inhibitors, and misses certain other patients who may respond. Therefore, there appears to be an unmet need for a better predictive biomarker that can identify patients that will likely benefit from ICI therapy.

The study’s researchers hypothesized that measuring the activity of the tumor microenvironment (TME) may be useful in patient selection for ICI therapy, and developed a novel algorithm that can be applied to gene expression data from a small set of most relevant genes, potentially making the assay practical and cost effective for clinical use.

“Unlike previously described biomarker models, the novel immuno-oncology algorithm behind DetermaIO measures the immunological state of the TME as a means to capture the interplay of the patient’s immune system and tumor immune evasion. Our hypothesis was that because the test measures the TME as a whole, the predefined threshold may have utility across several tumor types,” said Tyler Nielsen, lead author of the study and Senior Scientist at Oncocyte. “We established a threshold for positivity in triple negative breast cancer specimens, and as this study shows we were able to apply it to a non-small cell lung cancer cohort. We believe that this algorithm may give DetermaIO independent and incremental predictive value over the current gold standard biomarkers in the clinic.”

“As demonstrated by the translation of this signature from triple negative breast cancer to non-small cell lung cancer, the classifier appears to be applicable across multiple solid tumor types,” stated Doug Ross, M.D., Ph.D., and Chief Science Officer of Oncocyte. “We believe that DetermaIO may also be highly appealing for use in both pharma driven clinical studies and well as in the clinic. The test is currently performed centrally in our labs using our CLIA certified RT-PCR assay starting with very little tissue from biopsy specimens. The test utilizes gene expression data from any type of biopsy or surgical specimen, which can be generated on most NGS or PCR platforms, making it suitable for worldwide distribution. It can also be assessed on gene expression data that has often already been generated by pharmaceutical companies in their clinical trials, avoiding the need for tissue. This has been a very attractive value proposition to our pharmaceutical clients because we can help generate data quickly to demonstrate the utility of DetermaIO for their specific drug in development.”

Dr. Ross continued, “As DetermaIO works primarily by assessing the inflammatory cells and the cancer wound response, we are encouraged that DetermaIO may be relevant across multiple tumor types and useful in clinical studies being conducted by pharma companies, providing a means to distinguish patients likely to benefit from treatment with ICIs.”

Other key highlights of the study include:

• The study examined ten patients with two samples each—one from the tumor itself and one from the surrounding TME and used the algorithm to generate DetermaIO scores for each pair of matched samples. The agreement between the two samples across the ten patients was 92%. The ability to get concordant results from two different sampling sites may imply that DetermaIO will have greater flexibility in tissue requirements than similar tests.
• The DetermaIO score generated by the algorithm was applied to samples from lung cancer patients treated with ICI and was able to distinguish between tumors that responded to ICI and tumors that did not respond.
• The endpoint used in the study was sustained response, measured by no progression within six months. Using the six month response endpoint reflects DetermaIO’s ability to identify a durable response.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the Company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Oncocyte Forward Looking Statements. Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the potential clinical use of DetermaIO across multiple tumor types, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our or any distributor’s financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our or any distributor’s supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Media contact:
Terri Clevenger
Westwicke/ICR
203-856-4326
[email protected]

MILPITAS, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Numerous third-party integrations power the website supply chain. These integrations have access to critical and sensitive data and have become one of enterprise’s most glaring supply chain blind-spots. Tala Security, the global leader in web application data protection and client-side security, is pleased to announce Tala Detect. An industry-first platform solution specifically designed to secure and control critical, sensitive web data and enable compliance/risk management.

With the onset of regulations and the need for complete visibility, verification and control of private customer and business sensitive data, Tala Detect tracks data across three dimensions: exposure, capture and exfiltration/leakage and provides the means to control it.

• Sensitive Data Exposure: Which website integrations have access to what sensitive data?
• Sensitive Data Readers: Which website integrations read sensitive data?
• Sensitive Data Exfiltration: Which website integrations extract sensitive data?

The Tala Detect platform provides fine-grained data discovery, mapping and information flow analysis to identify sensitive data in forms, network requests, cookies and local/session storage. Synthetic JavaScript virtualization techniques also trace data, identifying complex workflows that can access, read and exfiltrate data, both intentionally and unintentionally. JavaScript risks are further enhanced with domain reputation analysis, leveraging internal and external threat feeds.

Tala Detect provides:

• Insights into the initiation chain or website calls that ultimately cause leakage of sensitive data.
• Analytics on risk patterns and Magecart IOC markers, alerting on possible compliance violations, website supply chain risks and vulnerabilities.
• Safeguarding of sensitive data from unauthorized access by both malicious and trusted third parties, ensuring compliance with data regulations as well as control over all data originating on enterprise web properties and applications.
• Tala provides invaluable reporting or Compliance/Risk management (CCPA/GDPR) and equips periodic audits, with insights, changes and patterns into website supply chain risk.

“Data Privacy Regulatory Compliance is driving enterprises to ensure they can control and safeguard data privacy for sensitive data originating on the web,” said Aanand Krishnan, Founder and CEO at Tala Security. “The modern website, powered by JavaScript, grants permissions and controls to a vast supply chain that very few enterprises have the ability to control. Tala Detect was designed specifically to assist enterprise website owners with ensuring continuous monitoring of data accessibility amongst this website supply chain together with the means to control it.”

With no need for integration into the customer environment, Tala’s actionable alerts and detailed reports ensure ongoing data privacy violation monitoring especially relevant for incident response, SOC, data protection and risk/compliance teams.

About Tala Security

Tala prevents sensitive data theft and client-side attacks like Magecart, XSS, code injections and session redirects. Our innovative solution is designed to secure customer data and ensure data privacy, without degrading site performance or top-line revenue. Tala’s technology automates policy generation, deployment and maintenance of powerful web standards, including CSP, SRI, Feature Policy, Referrer Policy, HSTS and others. Tala also leverages JavaScript virtualization synthetically to ensure data flow analysis of even the most complex workflows.

Tala’s comprehensive portfolio includes both Tala-Protect and Tala-Detect ensuring comprehensive data flow analysis together with the means to control it. This innovative combination of capabilities ensures attacks are prevented in real-time, data privacy and integrity are assured and the need for costly and continuous administration or incident response is minimized. Tala’s solutions have no impact on website performance or user experience – and no code integration is required.

Tala is led by industry veterans and successful entrepreneurs backed by an impressive collection of well-known tech investors, angels, former executives at Symantec and by the National Science Foundation (NSF). Our technology has garnered multiple awards including being named a Gartner Cool Vendor and an RSA Innovation Sandbox Finalist.

Learn more at https://www.talasecurity.io.

Contact

Sherri Walkenhorst
[email protected]
(801) 373-7888 

Click


here


to join the case

​LOS ANGELES, March 16, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Walmart, Inc. (“Walmart” or “the Company”) (NYSE: WMT) investors that acquired securities between March 30, 2016 and December 22, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that Walmart made misleading and false statements to the market. Walmart knowingly filled improper prescriptions that were written by “pill-mill” prescribers. Thousands of these prescriptions filled by Walmart demonstrated obvious red flags such as harmful mixtures of medications. Walmart management pressured its pharmacists to fill as many of these prescriptions as possible, which made it difficult for them to comply with the law. Walmart’s pharmacy revenues were inflated artificially, as a result of filling invalid prescriptions in violation of the dispensing requirements of the Controlled Substance Act. Walmart’s public statements were materially misleading and false throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Walmart, investors suffered damages.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

MCLEAN, Va., March 16, 2021 (GLOBE NEWSWIRE) — GTT Communications, Inc. (NYSE: GTT), a leading global cloud networking provider to multinational clients, announced today the appointment of Dave Salustri as Division President, Americas and Tom Homer as Division President, Europe. Mr. Salustri previously served as senior vice president Enterprise Sales, Americas. Prior to GTT, Mr. Salustri held a broad range of sales leadership and executive roles in the telecommunication industry at Time Warner Cable, XO Communications, and Verizon. Mr. Homer previously served as senior vice president, Europe, leading GTT’s sales operation in the region. Before joining GTT in 2020, Mr. Homer was Managing Director, EMEA at Telstra.

GTT’s divisions, aligned geographically, have responsibility for key functions that include client success, sales, sales engineering, quoting, ordering, professional services, and overall client account management. In their new roles, Mr. Salustri and Mr. Homer will focus on defining and executing the go-to-market strategy, expanding the breadth of services provided to GTT’s existing customer base, and acquiring new customers. These key areas of focus are supported by the company’s operational excellence and customer experience improvement initiatives coupled with its comprehensive portfolio of cloud networking services that address current and future enterprise telecommunications needs. In addition to Europe, Mr. Homer’s geographic responsibilities include Middle East, Africa, and Asia-Pacific.

“The extensive industry experience that Dave Salustri and Tom Homer offer, combined with their distinguished track records of achievement, is precisely the seasoned leadership talent that will enable GTT to exceed the business objectives of our two main divisions,” stated Ernie Ortega, GTT chief revenue officer and interim CEO. “Our emphasis on a customer-first culture, that has reshaped GTT’s strategic priorities, will be reinforced by the customer-centric approach that Dave and Tom bring to their new division leadership roles.”

About GTT

GTT connects people across organizations, around the world, and to every application in the cloud. Our clients benefit from an outstanding service experience built on our core values of simplicity, speed, and agility. GTT owns and operates a global Tier 1 internet network and provides a comprehensive suite of cloud networking services. For more information on GTT (NYSE: GTT), please visit www.gtt.net.

GTT Media Inquiries:


Rebecca Emery, LEWIS
+44-207-802-2626
[email protected]

GTT Investor Relations:


Carolyn Capaccio/Jody Burfening, LHA
+1-212-838-3777
[email protected]

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — Clarity Gold Corp. (“Clarity” or the “Company”) (CSE: CLAR, OTC: CLGCF, FSE: 27G) is pleased to welcome Mr. Olen Aasen to its Advisory Board. Mr. Aasen is an executive and corporate and securities lawyer with more than 14 years of experience in corporate, securities, mining and regulatory matters bringing a range of legal experience to Clarity’s team.

Mr. Aasen has been the Corporate Secretary, General Counsel or Vice President, Legal at various Canadian and U.S.-listed companies including TSX-listed Excelsior Mining Corp. Mr. Aasen has significant experience in working with mining companies through the development cycle and has advised on the successful completion of environmental assessments and permitting processes in Canada and the United States. In the past ten years Mr. Aasen has advised on over $800 million in debt and equity financings and structured project finance packages as well as advised on numerous critical project level agreements including rail transportation, power supply, port services, offtake, royalty, stream and Aboriginal impact benefits agreements. Mr. Aasen did his undergraduate studies in the Finance Department of the Sauder School of Business, obtained a J.D. from the University of British Columbia in 2006 and was called to the British Columbia Bar in 2007. Mr. Aasen was also appointed to the 2016 Legal 500 GC Powerlist for Canada.

“It’s an honour to welcome Olen as part of our Advisory team at Clarity,” said James Rogers, CEO of Clarity. “Olen’s legal experience in multiple aspects of the resource industry and finance and his proven reputational excellence are an asset for the company as we advance the Destiny Project.”

Issuance of Options

The Company is also pleased to announce that it has granted incentive stock options (each, an “Option”) to acquire an aggregate of 550,000 common shares of the Company (each, a “Share”) to certain consultants under its stock option plan. Each Option is exercisable for a period of two years expiring on March 15, 2023, at a price of $1.48 per Share. All the Options vested on the date of grant. The Options and the Shares issuable upon the exercise of the Options held by the optionees are subject to a hold period of four months from the date of grant of the Options.

About the Destiny Project

The 5,013 ha Destiny Project is located in the prolific Abitibi Greenstone Belt along a major structural break which is largely underexplored. The project has excellent infrastructure, with road access approximately 75 km NNE of the city of Val d’Or and has considerable work done to date including over 50,000 m of diamond drilling.

For a more detailed account, the reader is encouraged to refer to the Company’s website.

About Clarity

Clarity Gold Corp. is a Canadian mineral exploration company focused on the acquisition, exploration and development of gold projects in Canada. The Company has entered into an option agreement to purchase 100% of the Destiny Project, Clarity’s flagship asset, a gold-focused project in the mineral rich Abitibi region in Quebec. The Company is based in Vancouver, British Columbia, and is listed on the CSE under the symbol “CLAR”. To learn more about Clarity Gold Corp. and its projects please visit www.claritygoldcorp.com.

ON BEHALF OF THE BOARD

“James Rogers”
Chief Executive Officer
Tel: 1 (833) 387-7436
Email: [email protected]
Website: claritygoldcorp.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding that the new advisory board member’s technical experience and track record of management and project evaluation will be immensely valuable to the Company. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Risks that could change or prevent these statements from coming to fruition include, but are not limited to, general market conditions and other factors beyond the direct control of the Company. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

 

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — American Pacific Mining Corp. (“American Pacific” or the “Company”) (CSE:USGD, OTCQB:USGDF) is pleased to announce the planned 2021 exploration program at the Madison Copper Gold Project (the “Madison Project”), located in Montana, USA.

The Company’s wholly-owned Madison Project is currently under an earn-in with Option to joint venture agreement, whereby Kennecott Exploration Company (“Kennecott”), part of the Rio Tinto Group, may spend $30 million USD to earn up to 70% (see news release dated June 26, 2020).

Beginning in the first half of 2021, Kennecott’s exploration program at Madison is expected to include diamond drilling, reverse circular (“RC”) drilling, road construction, extensive rock-chip and soil sampling and a MAG survey. The exploration plan is being permitted for success and may include up to 31 diamond drilling holes and up to 50 RC holes. This exploration will focus on extending the five jasperoid zones and three massive sulfide zones as well as testing for skarn mineralisation, porphyry and gold potential.

ANTICIPATED EXPLORATION PLANS:

Madison Jasperoid Targets

• Three diamond drill sites are planned to test the extensions (100m step-outs) of the Kettlehouse and Philipsburg jasperoids as well as testing the potential for additional jasperoids in zones of dilation.
• A 4^th core hole is planned to test an additional 80m step out of the Kettlehouse Jasperoid to the southwest.
• A 5^th core hole is planned using the existing site at MADN0022.
• Note that all drill sites will be permitted to allow for up to 5 drill holes at each site.

Madison Skarn – Massive Sulphides

• Three diamond drill sites are planned to test the extensions of massive sulphide bodies close to the granodiorite contact in structurally favourable locations.
• Note that all drill sites will be permitted to allow up to 5 drill holes each.

Figure 1. Madison Project Map Showing 2021 Interpretive Mineralization and Target Areas

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7ea0a4f0-7d34-4cdd-9033-b10a45393ef4

Previous drill holes mentioned in Figure 1 above can be found in the technical report titled “NI 43-101 Technical Report for the Madison Project, Madison County, Montana USA” dated February 22, 2019 and effective as of March 4, 2019 which was prepared in accordance with National Instrument 43-101 – Standards for Disclosure for Mineral Projects (“NI 43-101”) at Microsoft Word – BRD TechReport Update Nov_Dec2018_Final Draft March 6 (americanpacific.ca)

Skarn repetition/Porphyry Potential

• At least 1 drill site is planned to test the magnetic high east of the Madison-Broadway skarn hosted mineralization (see map below).
• Note that all drill sites will be permitted to allow up to 5 drill holes each.

Figure 2. Madison Project 2021 Magnetic Anomaly Map

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72ef73a5-0512-41c1-97e1-f53afad030e9

Gold Exploration

Phase 1

• Approximately 1000m of road construction will test cross-cutting zones of high-grade gold mineralization in veins.
• Where warranted, road cuts will also be cleaned up, mapped and sampled.
• Surface channel sampling of the American Mine area is also planned.

Phase 2

• Road construction will be followed up with RC drilling.
• Kennecott is currently permitting for up to 10 RC sites. Additional drill sites and possible trenches will be permitted under a Plan of Operation based upon program success.
• Note that all drill sites will be permitted to allow up to 5 drill holes each.

Permitting

• A Notice of Intent has been filed with the Bureau of Land Management (“BLM”) for up to 5 acres of disturbance to include road construction, road building, and drill pad construction.
• A notice has been filed for drill sites on private land.
• A Plan of Operation that would allow surface disturbance of more than 5 acres is underway and will be filed with the BLM shortly.

Eric Saderholm, President of American Pacific stated: “American Pacific is looking forward to the extensive and multi-faceted 2021 exploration program at Madison. We anticipate further definition and extension of the skarn, jasperoid and massive sulphide mineralization from the drilling program. Road construction and detailed mapping should expose hidden mineralization and additional geophysical work will further refine target generation.”

Qualified Person

Technical aspects of this press release have been reviewed and approved by Eric Saderholm, P.Geo., the designated Qualified Person (QP) under NI 43-101.

About American Pacific Mining Corp.

American Pacific Mining Corp. is a precious metals explorer focused on gold and silver opportunities in the Western United States. The Madison Mine in Montana, under option to joint venture with Kennecott Exploration Company, is the Company’s flagship asset. The Gooseberry Gold-Silver Project under option to GRAC Global Resource Acquisition Corp. and the Tuscarora Gold Project, under option to Soldera Mining, are two high-grade, precious metals projects located in key mining districts of Nevada. The Company’s mission is to grow by the drill bit and by acquisition.

On Behalf of the Board of American Pacific Mining Corp.

“Warwick Smith”
CEO & Director

Corporate Office: Suite 910 – 510 Burrard Street Vancouver, BC, V6C 3A8 Canada
Contact Kristina Pillon, President, High Tide Consulting Corp., 604.908.1695 / [email protected]

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SINGAPORE, March 16, 2021 (GLOBE NEWSWIRE) — Truera, which provides the first Model Intelligence platform for AI explainability and model quality, announced today that it has been selected to co-lead the workstream on transparency in the industry initiative on Responsible AI led by the Monetary Authority of Singapore (The Veritas Consortium).

Truera will be represented by Anupam Datta and Shameek Kundu. Datta – co-founder, president and chief scientist at Truera – is also a professor at Carnegie Mellon University, where over the past decade he has led groundbreaking research in the areas of AI explainability and governance as well as privacy and data protection. Datta is active in building the explainability and trustworthy AI community, and regularly gives expert talks, serves on conference organizing and program committees, and works with regulatory agencies on this topic. Datta obtained PhD and MS degrees from Stanford University and a BTech from the Indian Institute of Technology, Kharagpur, all in Computer Science.

Shameek Kundu is the Head of Financial Services and Chief Strategy Officer at Truera. Previously he was Chief Data Officer at Standard Chartered Bank, where he led the effort to adopt AI and advanced analytics in multiple areas, including credit and financial crime compliance. Kundu played an active role in drafting the Monetary Authority of Singapore’s AI guidelines in 2018. He is a member of the Bank of England’s AI Public-Private Forum and the OECD Global Partnership on AI.

The Veritas Consortium was established in 2019 to address implementation challenges in the responsible use of AI and data analytics at financial institutions. In Phase One (recently completed), Veritas explored the development of a fairness assessment methodology in credit risk scoring and customer marketing. In Phase Two, Veritas will look into developing the Ethics, Accountability and Transparency assessment methodology for the two use cases in Phase One. Phase Two will also include use cases for the insurance industry. Truera will co-lead the Transparency Working Group in Phase Two.

The consortium includes major global and regional banks (e.g., Citibank, DBS, Goldman Sachs, HSBC, Standard Chartered), insurers (e.g., Axa, Swiss Re, Prudential, Ping An) and technology firms (e.g., Accenture, Microsoft). The full list of members can be found here.

“Veritas is a collaborative effort among financial institutions, vendors, and the MAS to establish best practices and open source software to ensure fairness, ethics, accountability and transparency while adopting AI,” said Datta. “This work is absolutely critical, and we are honored to play a part in it.”

Truera, which launched in August 2020, has already made a significant impact in the AI space. The Truera platform is already deployed at and delivering value to a number of Fortune 100 customers, including global bank Standard Chartered. In December 2020, Truera announced a $12M funding round to help accelerate the go-to-market of its AI Model Intelligence Platform. In March 2021, the company was named to Fast Company’s Annual List of the World’s Most Innovative Companies for AI.

To learn more about the Veritas initiative, visit https://www.mas.gov.sg/schemes-and-initiatives/veritas. To learn more about Truera or schedule a demo, visit https://truera.com/.

About Truera


Truera
provides the first Model Intelligence platform, to help enterprises analyze machine learning, improve and monitor model quality and build trust. Powered by enterprise-class Artificial Intelligence (AI) Explainability technology based on six years of research at Carnegie Mellon University, Truera’s platform helps eliminate the black box surrounding widely used AI and ML technologies. This visibility leads to higher quality, explainable models that sustainably achieve measurable business results, address unfair bias, and ensure governance and compliance. To learn more, visit https://truera.com/.

Media contact:

Michelle Faulkner
617-510-6998
[email protected]

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire – InsuraGuest Technologies, Inc.® (TSX-V: ISGI) (OTCQB: ISGIF) (“InsuraGuest” or the “Company”), through its wholly owned U.S. subsidiary InsuraGuest RPG (“ISG”), is proud to announce it has launched a new product called Limited-Service Hospitality Liability coverages, which will be offered to franchise limited-service hotels that have less than 100 rooms and an average daily rate (ADR) that is less than US$100 per night.

According to the American Hotel and Lodging Association, the U.S. has over 55,900 properties nationwide, of which 33,000 are limited-service hotels. Additionally, there are 5.3 million guest rooms, which accommodate 1.3 billion guest nights annually. The U.S. hotel industry employed one in 25 workers and added $660 billion to the U.S. GDP in 2019.

“Franchised limited-service hotels make up 59% of the U.S. market, so we have designed a solution at a price point that meets their needs while protecting their properties on a primary basis,” states Douglas Anderson, chairman and CEO of InsuraGuest Technologies, Inc. 

Property Management System Integration


InsuraGuest now integrates with 82 different property management systems through its proprietary API, which enables an organization to transfer certain liability exposures to the InsuraGuest carrier. By transferring certain liabilities to InsuraGuest Hospitality Liability coverages, the covered hotel or vacation rental property can lower its claim ratio and risk profile, which may decrease the property’s general liability premiums.

Created specifically for InsuraGuest, the Hospitality Liability policy is issued by InsuraGuest Risk Purchasing Group, LLC, and is administered by InsuraGuest Insurance Agency, LLC. CA/LIC: 6001686

InsuraGuest Technologies Inc.

Harnessing the Power of Technology to Reinvent Insurance

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF) is an insurtech (insurance+technology) company that is disrupting the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple sectors. We are transforming the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold.
CA/LIC: 6001686

For more information, visit: www.InsuraGuest.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. There is no assurance that this new business product offering or other planned products will be successful. The insurance industry is intensely competitive in the business owner policy sector, and the Company’s competitors have significantly more resources than the Company. Acceptance by potential customers is difficult to predict, particularly in the case of new products and disruptive technologies. If the Company fails to achieve market acceptance it will significantly impact its results and financial resources. Achieving market acceptance may require advertising budgets that exceed the Company’s current resources and require the Company to seek additional debt or equity financing. There is no assurance that such financing will be available at reasonable prices or at all.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Company Contact:

Investor Relations
+1-212-466-6200 ext. 1
[email protected]  

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]